On November 5, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the third quarter ending September 30, 2024, along with key business highlights. The company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities. Research and development expenses decreased compared to the previous year, and the company experienced a net loss of $85.9 million for the quarter, an improvement over the prior year's net loss. CRISPR Therapeutics also provided updates on its product pipeline, including the regulatory approval of CASGEVY for SCD and TDT in Switzerland and Canada, the activation of 45 treatment centers globally, and the collection of cells from approximately 40 patients. The company highlighted ongoing clinical trials for its next-generation CAR T...Show More

On November 5, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the third quarter ending September 30, 2024, along with key business highlights. The company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities. Research and development expenses decreased compared to the previous year, and the company experienced a net loss of $85.9 million for the quarter, an improvement over the prior year's net loss. CRISPR Therapeutics also provided updates on its product pipeline, including the regulatory approval of CASGEVY for SCD and TDT in Switzerland and Canada, the activation of 45 treatment centers globally, and the collection of cells from approximately 40 patients. The company highlighted ongoing clinical trials for its next-generation CAR T product candidates, CTX112 and CTX131, and its in vivo gene editing product candidates, CTX310 and CTX320. Additionally, CRISPR Therapeutics is advancing CTX211, a treatment for Type 1 Diabetes, and expects to initiate clinical trials for CTX340 and CTX450 in the second half of 2025. The company's collaboration with Vertex Pharmaceuticals continues, with Vertex leading the global development, manufacturing, and commercialization of CASGEVY.